SAMSUNG BIOLOGICS Co., Ltd.

As of June 30, 2026, SAMSUNG BIOLOGICS Co., Ltd. carries a market capitalization of 63.89T, placing it among publicly traded companies globally. Its enterprise value stands at 62.91T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SAMSUNG BIOLOGICS Co., Ltd.'s next confirmed earnings release is scheduled for January 27, 2027.

As of June 30, 2026, SAMSUNG BIOLOGICS Co., Ltd. has 46.24M shares outstanding.

As of June 30, 2026, SAMSUNG BIOLOGICS Co., Ltd. trades at a trailing price-to-earnings ratio of 32.26. The price-to-sales ratio is 14.08, and the price-to-book ratio stands at 7.64.

As of June 30, 2026, SAMSUNG BIOLOGICS Co., Ltd. trades at an EV/EBITDA multiple of 22.69 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 13.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27.67 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. SAMSUNG BIOLOGICS Co., Ltd. trades at an EV/FCF ratio of 39.45, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 62.91T versus a market cap of 63.89T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SAMSUNG BIOLOGICS Co., Ltd. maintains a current ratio of 1.80, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.84, indicating elevated leverage, while an interest coverage ratio of 103.02 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SAMSUNG BIOLOGICS Co., Ltd. posted a return on equity (ROE) of 19.88, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 14.61 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 13.04, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.72, useful for judging operating efficiency across full business cycles. The company generates approximately 850.83M in revenue per employee across its workforce of 5,344.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.78 indicates how many times SAMSUNG BIOLOGICS Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SAMSUNG BIOLOGICS Co., Ltd. recorded 621.27B in income tax expense. That works out to an effective tax rate of 25.51, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.44T, leaving 1.98T in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, SAMSUNG BIOLOGICS Co., Ltd.'s stock has declined approximately 17.44% over the past 52 weeks. The 50-day moving average sits at 1.43M, while the 200-day moving average is 1.51M.

Over the twelve months ended June 30, 2026, SAMSUNG BIOLOGICS Co., Ltd. generated 4.55T in revenue and converted that into 1.98T in net income, yielding earnings per share of 39,159.91. EBITDA reached 2.77T, while operating income came in at 2.27T.

As of June 30, 2026, SAMSUNG BIOLOGICS Co., Ltd. holds 2.21T in cash and equivalents against 1.24T in total debt, resulting in a net debt position of 676.78B. Total book value stands at 8.36T, with working capital of 2.36T providing operational flexibility.

SAMSUNG BIOLOGICS Co., Ltd. produced 2.43T in operating cash flow over the twelve months ended June 30, 2026. After subtracting -859.26B in capital expenditures, free cash flow totaled 1.57T - equivalent to 33,988.05 per share.

Over the twelve months ended June 30, 2026, SAMSUNG BIOLOGICS Co., Ltd. posted a gross margin of 53.76, reflecting its pricing power and cost economics. The operating margin of 50.02 and net profit margin of 43.64 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.46, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.80, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to SAMSUNG BIOLOGICS Co., Ltd. shareholders.

SAMSUNG BIOLOGICS Co., Ltd.'s most recent stock split took place on October 2, 2026 with a 442:445 split ratio.

As of June 30, 2026, SAMSUNG BIOLOGICS Co., Ltd. has an Altman Z-Score of 10.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.